Key result
Combination antihypertensives fail to reduce mortality or admission vs monotherapy in nonsurgical type B aortic dissection.
Why the study?
The use of medication to treat nonsurgical type B aortic dissection remains unclear in the studied population.
Do dual or triple antihypertensive strategies improve outcomes compared to monotherapy in patients with nonsurgical type B aortic dissection?
Cohort (n=106)
No
Do dual or triple antihypertensive strategies improve outcomes compared to monotherapy in patients with nonsurgical type B aortic dissection?
In patients with nonsurgical type B aortic dissection, dual or triple antihypertensive therapy did not significantly improve outcomes compared to monotherapy.
Dual or triple antihypertensive therapy was not associated with lower mortality or admissions versus monotherapy in nonsurgical type B aortic dissection; leaves open optimal regimen pending randomized trials.
Aortic dissection is a life-threatening condition. However, the use of medication to treat it remains unclear in our population, particularly in patients with a type B aortic dissection (TBAD) who do not receive surgery. This retrospective cohort study evaluated antihypertensive prescription patterns and outcomes in patients with nonsurgical TBAD. We reviewed the hospital records of patients with TBAD at a medical center in Taiwan from January 2008 to June 2013 to assess the baseline information, prescribing pattern, event rate, and clinical effectiveness of different antihypertensive treatment strategies. A Cox proportional hazards model was used to estimate outcomes in different antihypertensive strategies. The primary endpoints were all-cause mortality and hospital admission for an aortic dissection. We included 106 patients with a mean follow-up period of 2.75 years. The most common comorbidity was hypertension followed by dyslipidemia and diabetes mellitus. Study endpoints mostly occurred within 6 months after the index date. Over 80% of patients received dual or triple antihypertensive strategies. Patients treated with different treatment strategies did not have a significantly increased risk of a primary outcome compared with those treated with a monotherapy. We found no significant difference in the primary outcome following the use of different antihypertensive medication regimes.
No takes yet. Share an insight, caveat, or question.
Liao et al. (2016) conducted a cohort in Nonsurgical type B aortic dissection (n=106). Dual or triple antihypertensive strategies vs. Monotherapy was evaluated on All-cause mortality and hospital admission for an aortic dissection. Different antihypertensive treatment strategies did not significantly alter the risk of all-cause mortality or hospital admission compared with monotherapy in nonsurgical type B aortic dissection.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: